M&A / Deals Pfizer signs licence agreement with Chai for AI drug discovery Pharmaceutical TechnologyPfizer and Chai Discovery have signed a licence deal enabling the former to incorporate Chai's AI platform into its drug discovery operations.Read full story pharminent June 5, 2026 (Last updated: June 5, 2026) Pharmaceutical Technology Pfizer and Chai Discovery have signed a licence deal enabling the former to incorporate Chai’s AI platform into its drug discovery operations. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Boan Biotech Submits BLA to FDA for Two Denosumab BiosimilarsNext: Biogen’s salanersen gains FDA breakthrough therapy designation for SMA Related Stories M&A / Deals Spero snaps up Innovent immunology drug in strategic pivot pharminent July 14, 2026 M&A / Deals AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B pharminent July 14, 2026 M&A / Deals Novartis and Chai Discovery collaborate on antibody identification pharminent July 14, 2026
